No Detail Found!

The Teratogenic Effect of Semaglutide Drug on the Histological Structure of the Lungs in the Albino Mouse (Mus musculus )

Author(s)
Saba Dawod Salman Department of Science, College of Basic Education, Mustansiriyah University, Baghdad, Iraq
Abstract
Objectives: Background: The current study aimed to determine the teratogenic effect of the drug Semaglutide on the histological structure of the lungs in the albino mouse. Methods: The experimental mice were injected with the drug Semaglutide for a period of thirty days at a concentration of 14 mg/kg/day. Twenty male albino mice of Mus musculus type were used. They were randomly divided into two groups. Each group included 10 mice. The animals were randomly divided into two groups. The control group was administered physiological saline for 30 days, whereas the treated group was administered Semaglutide at a dose of 14 mg/kg/day for 30 consecutive days. At the end of the experimental period, the animals were anesthetized and sacrificed. The lungs were removed and fixed, then embedded in paraffin wax. Tissue sections were prepared and stained with Hematoxylin and Eosin (H&E). The sections were examined under a light microscope. Result: The results of examination of histological sections of the lungs in the experimental groups dosed with the drug showed the occurrence of pathological histopathological changes represented by the detachment of the epithelial layer of the bronchioles from the layer of the basement membrane on which it rests and its accumulation in the lumen of the bronchioles, with the occurrence of necrosis and degeneration in their walls and congestion of the blood vessels, accompanied by bleeding in some parts. Also, increased the thickness of the alveolar walls and their ducts, in addition to the expansion of the alveoli, degeneration and destruction of the alveolar walls, infiltration of inflammatory cells and thickening of the nuclei, swelling and bronchial degeneration were observed, in addition to the occurrence of fibrosis. The lungs showed blood vessel deformation and congestion, alveolar bleeding, fibrosis around vessels and bronchioles and swollen alveolar cells with thickened nuclei.
Publication Details
Page(s) 170-175
DOI DOI not available
Published Journal: Journal of Pioneering Medical Sciences, Volume: 15, Issue: 2, Year: 2026

Request the full text from PASTIC

Keywords
Teratogenic Effect, Histological structure, Albino mouse, Semaglutide, Lungs
References
Doggrell S.A. .2018 .Semaglutide in Type 2 Diabetes - Is It the Best Glucagon-Like Peptide 1 Receptor Agonist (GLP-1R Agonist)?” Expert Opinion on Drug Metabolism ansd Toxicology. , 1441286(2018) : 371-377.
Goldenberg R.M.,Steen O. .2018 .Review and Place in Therapy for Adults with Type 2 Diabetes. Canadian Journal of Diabetes, 05(2019) : 136-145.
.2022 .. , : .
Bradley C.L. . .Tirzepatide, the newest medication for type 2 diabetes: A review of the literature and implications for clinical practice. The Annals of Pharmacotherapy, 57(2023) : 822-836.
Dougherty T.,Heile M. .2020 .Type 2 diabetes in the US managed care setting: The burden of disease and rationale for an oral glucagon-like peptide-1 receptor agonist. The American Journal of Managed Care, 88552(16 Suppl.) : S325-S334.
Singh G. .001952 .Wegovy (Semaglutide): A new weight loss drug for chronic weight management. ” Journal of Investigative Medicine, 70(2022) : 5-13.
Phillips A.,Clements J.N. . .Clinical review of subcutaneous semaglutide for obesity. ” Journal of Clinical Pharmacy and Therapeutics, 47(2022) : 184-193.
Amaro A. .2022 .Efficacy and safety of semaglutide for weight management: evidence from the STEP program. Postgraduate Medicine, 2147326(2022) : 5-17.
Capla J,Hanna S.A. .2023 .Patient evaluation and surgical staging. ” Clinics in Plastic Surgery, 07(2024) : 7-12.
Liebisch-Rey H. .2023 .The short-term cost-effectiveness of once-weekly semaglutide versus once-weekly dulaglutide for the treatment of type 2 diabetes mellitus in colombian adults. ” F1000Research, 12 : 914.
Chen J. .2022 .GLP-1 receptor agonist as a modulator of innate immunity. , 997578 : 997578.
Millar B.,M. de Gaetano B. .2023 .“Posing the rationale for synthetic Lipoxin mimetics as an adjuvant treatment to gold standard atherosclerosis therapies. , 1125858 : 1125858.
Andersen D.B. and J.J.,Holst D.B. and J.J. .2021 .Peptides in the regulation of glucagon secretion. ” Peptides, 170683 : 170683.
Queiroz V. N. F. .2023 .Risk of pulmonary aspiration during semaglutide use and anesthesia in a fasting patient: A case report with tomographic evidence. Einstein (São Paulo), 21 : .
Tsamos G. .2023 .Therapeutic potentials of reducing liver fat in non-alcoholic fatty liver disease: Close association with type 2 diabetes. ” Metabolites, 13 : 517.
Sodhi M. .2023 .Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. ” JAMA, 19574(18) : 1795-1797.
Lenharo M. .2023 .Anti-Obesity drugs' side effects: What we know so far. ” Nature, 622(7984) : 682.
Silbert R. . .Hypoglycemia among patients with type 2 diabetes: Epidemiology, risk factors and prevention strategies. ” Current Diabetes Reports, 18(2018) : 53.
Aroda V.R. . .Safety and tolerability of semaglutide across the SUSTAIN and PIONEER Phase IIIa clinical trial programmes. ” Diabetes, Obesity & Metabolism, 25(2023) : 1385-1397.
Nevola R. . .GLP-1 receptor agonists in non-alcoholic fatty liver disease: Current evidence and future perspectives. International Journal of Molecular Sciences, 24(2023) : 1703.
Flint A. . .Randomised clinical trial: Semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. ” Alimentary Pharmacology and Therapeutics, 54(2021) : 1150-1161.
Bandyopadhyay S. .2023 .Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis. ” Diabetes and Metabolic Syndrome, 102849(10) : 102849.
Suvarna S. K.,Elsevier S. K. .2019 .. Bancroft's Theory and Practice of Histological Techniques. 8th Edn, : .
Jo T. .2021 .Risk of drug-induced interstitial lung disease in hospitalised patients: A nested case-control study. ” Thorax, 76(12) : 1193-1199.
Rossi S.E. . .Pulmonary drug toxicity: Radiologic and pathologic manifestations. ” Radiographics, 20(2000) : 1245-1259.
Zoccali C. .2013 .Lung congestion as a risk factor in end-stage renal disease. ” Blood Purification, 36 : 184-191.
Ceridon M. .2009 .Does the bronchial circulation contribute to congestion in heart failure?” Medical Hypotheses. , 03(2009) : 414-419.
Ahmed S.T. . .The histological effects of methotrexate on the lungs of albino rats: An experimental study. European Journal of Molecular and Clinical Medicine, 8(2021) : 1289-1297.
Drent M. . .Drug-induced pneumonitis and heart failure simultaneously associated with venlafaxine. American Journal of Respiratory and Critical Care Medicine, 167(2003) : 958-961.
Sunaga H. .2013 .Deranged fatty acid composition causes pulmonary fibrosis in Elovl6-deficient mice. Nature Communications, 4 : .
Wynn T.A. . .Pulmonary fibrosis: Pathogenesis, etiology and regulation. ” Mucosal Immunology, 2(2009) : 103-121.
Petta A.D. . .Histopathological characteristics of pulmonary emphysema in experimental model. ” Einstein, 12(2014) : 382-383.
Sarhan O.M. .2020 .Impact effect of methyl tertiary-butyl ether: Twelve months vapor inhalation study in rats. ” Biology, 9(2) : .
Parekh D. . .Acute lung injury. Clinical Medicine, 11(2011) : 615-618.
Assaad S. . .Assessment of pulmonary edema: Principles and practice. ” Journal of Cardiothoracic and Vascular Anesthesia, 32(2017) : 901-914.
.2016 .. , : .
0

Citations

0

Downloads

18

Views